Important Biotech Catalysts For September 7, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6…
Dow Jumps 450 Points; UiPath Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow Jones adding around 450 points on Wednesday.
Glaukos Inks Licensing Pact For Rare Eye Disorder Treatment
iVeena Delivery Systems Inc has entered into a strategic licensing agreement with Glaukos Corporation (NYSE:GKOS), granting an exclusive global license to develop and…
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application…
Stifel Upgrades Glaukos to Buy, Raises Price Target to $60
Stifel analyst Thomas Stephan upgrades Glaukos (NYSE:GKOS) from Hold to Buy and raises the price target from $40 to $60.
Citigroup Maintains Neutral on Glaukos, Lowers Price Target to $43
Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:GKOS) with a Neutral and lowers the price target from $58 to $43.
Glaukos Q1 Adj. EPS $(0.38) Beats $(0.50) Estimate, Sales $67.70M Beat $60.85M Estimate
Glaukos (NYSE:GKOS) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.50) by 24 percent. This is a 80.95 percent decrease over losses of $(0.21) per share from the same
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Sight Sciences’ Q4 Earnings, FY22 Guidance Beat Street View
Sight Sciences Inc (NASDAQ: SGHT) has